Vernakalant, sold under the brand name Brinavess, is a class III antiarrhythmic drug for the acute conversion of atrial fibrillation, in form of an intravenous infusion. It has been approved for use in the European Union and the United Kingdom since 2010. The US Food and Drug Administration denied approval in 2008 and 2019.
{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 446573380 | IUPAC_name = (3R)-1-{(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl}pyrrolidin-3-ol | image = Vernakalant.svg | image_class = skin-invert-image | alt =
| tradename = Brinavess | pregnancy_AU = | pregnancy_category = | routes_of_administration = Intravenous, | ATC_prefix = C01 | ATC_suffix = BG11
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).